{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T08:21:10Z","timestamp":1783066870953,"version":"3.54.6"},"reference-count":32,"publisher":"Galenos Yayinevi","issue":"1","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Turk J Phys Med Rehab"],"accepted":{"date-parts":[[2021,7,30]]},"published-print":{"date-parts":[[2022,3,1]]},"abstract":"<jats:p>Objectives: The aim of this study was to investigate the role of serum niacin and dopamine (DA) levels and their clinical importance in fibromyalgia syndrome (FMS) patients.<\/jats:p>\n                  <jats:p>Patients and methods: Between April 2018 and October 2018, a total of 53 female patients (mean age: 38.3\u00b15.5 years; range, 21 to 45 years) with a clinical diagnosis of FMS and 35 healthy female controls (mean age: 36.7\u00b15.2 years; range, 25 to 44 years) were included in this cross-sectional study. The Visual Analog Scale (VAS), Beck Depression Inventory (BDI), and Fibromyalgia Impact Questionnaire (FIQ) were applied to the patients. Serum levels of niacin and DA were measured by high-performance liquid chromatography (HPLC) and enzyme-linked immunosorbent assay (ELISA) methods, respectively.<\/jats:p>\n                  <jats:p>Results: Niacin and DA levels of the patient group were significantly lower than those of control group (p=0.003 and p=0.02, respectively). A very strong positive correlation was found between niacin and DA levels (r=0.96 p&lt;0.001). Evaluation of the diagnostic performance of niacin and DA by the receiver operating characteristic analysis yielded an area under the curve (AUC) of 0.73 (p&lt;0.001, 95% confidence interval [CI]: 0.62-0.85) and an AUC of 0.68 (p=0.004, 95% CI: 0.56-0.80), respectively.<\/jats:p>\n                  <jats:p>Conclusion: Serum niacin and DA levels decrease in FMS patients in relation to the tender point numbers. It can be suggested that the levels of these two markers can be considered additional tools in the diagnosis of FMS.<\/jats:p>","DOI":"10.5606\/tftrd.2022.8529","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T12:54:05Z","timestamp":1648558445000},"page":"84-90","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of clinical relationship of serum niacin and dopamine levels in patients with fibromyalgia syndrome"],"prefix":"10.4274","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6296-2390","authenticated-orcid":false,"given":"Muzaffer","family":"Katar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7491-1569","authenticated-orcid":false,"given":"H\u00fclya","family":"Deveci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1531-8567","authenticated-orcid":false,"given":"K\u00f6ksal","family":"Deveci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2811","published-online":{"date-parts":[[2022,3,1]]},"reference":[{"key":"ref-1","doi-asserted-by":"crossref","unstructured":"Heinricher MM, Tavares I, Leith JL, Lumb BM. Descending control of nociception: Specificity, recruitment and plasticity. Brain Res Rev 2009;60:214-25.","DOI":"10.1016\/j.brainresrev.2008.12.009"},{"key":"ref-2","doi-asserted-by":"crossref","unstructured":"Meeus M, Nijs J. Central sensitization: A biopsychosocial explanation for chronic widespread pain in patients with fibromyalgia and chronic fatigue syndrome. Clin Rheumatol 2007;26:465-73.","DOI":"10.1007\/s10067-006-0433-9"},{"key":"ref-3","doi-asserted-by":"crossref","unstructured":"Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum 1990;33:160-72.","DOI":"10.1002\/art.1780330203"},{"key":"ref-4","doi-asserted-by":"crossref","unstructured":"Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010;62:600-10.","DOI":"10.1002\/acr.20140"},{"key":"ref-5","doi-asserted-by":"crossref","unstructured":"Hagelberg N, J\u00e4\u00e4skel\u00e4inen SK, Martikainen IK, Mansikka H, Forssell H, Scheinin H, et al. Striatal dopamine D2 receptors in modulation of pain in humans: A review. Eur J Pharmacol 2004;500:187-92.","DOI":"10.1016\/j.ejphar.2004.07.024"},{"key":"ref-6","doi-asserted-by":"crossref","unstructured":"Altier N, Stewart J. The role of dopamine in the nucleus accumbens in analgesia. Life Sci 1999;65:2269-87.","DOI":"10.1016\/S0024-3205(99)00298-2"},{"key":"ref-7","unstructured":"Burkham J, Harris E. Fibromyalgia: a chronic pain syndrome. In: Harris E, Budd R, Genovese M, Firestein G, Sargent J, editors. Kelley\u2019s textbook of rheumatology. 7th ed Philadelphia: WB Saunders; 2005. p. 522-36."},{"key":"ref-8","doi-asserted-by":"crossref","unstructured":"Gasperi V, Sibilano M, Savini I, Catani MV. Niacin in the central nervous system: An update of biological aspects and clinical applications. Int J Mol Sci 2019;20:974.","DOI":"10.3390\/ijms20040974"},{"key":"ref-9","doi-asserted-by":"crossref","unstructured":"Swerdlow RH. Is NADH effective in the treatment of Parkinson's disease? Drugs Aging 1998;13:263-8.","DOI":"10.2165\/00002512-199813040-00002"},{"key":"ref-10","doi-asserted-by":"crossref","unstructured":"Kurtze N, Svebak S. Fatigue and patterns of pain in fibromyalgia: Correlations with anxiety, depression and co-morbidity in a female county sample. Br J Med Psychol 2001;74:523-37.","DOI":"10.1348\/000711201161163"},{"key":"ref-11","doi-asserted-by":"crossref","unstructured":"Ellis SD, Kelly ST, Shurlock JH, Hepburn ALN. The role of vitamin D testing and replacement in fibromyalgia: A systematic literature review. BMC Rheumatol 2018;2:28.","DOI":"10.1186\/s41927-018-0035-6"},{"key":"ref-12","doi-asserted-by":"crossref","unstructured":"Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An  inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-71.","DOI":"10.1001\/archpsyc.1961.01710120031004"},{"key":"ref-13","unstructured":"Hisli N. A study on validity and reliability test of the Beck Depression Scale. Journal of Psychology 1988;6:118-22."},{"key":"ref-14","unstructured":"Bennett R. The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics and uses. Clin Exp Rheumatol 2005;23(5 Suppl 39):S154-62."},{"key":"ref-15","doi-asserted-by":"crossref","unstructured":"Sarmer S, Ergin S, Yavuzer G. The validity and reliability of the Turkish version of the Fibromyalgia Impact Questionnaire. Rheumatol Int 2000;20:9-12.","DOI":"10.1007\/s002960000077"},{"key":"ref-16","doi-asserted-by":"crossref","unstructured":"Elma \u00d6, Yilmaz ST, Deliens T, Coppieters I, Clarys P, Nijs J, et al. Do nutritional factors interact with chronic musculoskeletal pain? A systematic review. J Clin Med 2020;9:702.","DOI":"10.3390\/jcm9030702"},{"key":"ref-17","doi-asserted-by":"crossref","unstructured":"Latremoliere A, Woolf CJ. Central sensitization: A generator of pain hypersensitivity by central neural plasticity. J Pain 2009;10:895-926.","DOI":"10.1016\/j.jpain.2009.06.012"},{"key":"ref-18","doi-asserted-by":"crossref","unstructured":"Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: Tests for correlation and regression analyses. Behav Res Methods 2009;41:1149-60.","DOI":"10.3758\/BRM.41.4.1149"},{"key":"ref-19","unstructured":"Muss C, Mosgoeller W, Endler T. Mood improving Potential of a Vitamin Trace Element Composition--A randomized, double blind, placebo controlled clinical study with healthy volunteers. Neuro Endocrinol Lett 2016;37:18-28."},{"key":"ref-20","doi-asserted-by":"crossref","unstructured":"Farmer MA, Baliki MN, Apkarian AV. A dynamic network perspective of chronic pain. Neurosci Lett 2012;520:197-203.","DOI":"10.1016\/j.neulet.2012.05.001"},{"key":"ref-21","doi-asserted-by":"crossref","unstructured":"Gao X, Zhang Y, Wu G. Effects of dopaminergic agents on carrageenan hyperalgesia in rats. Eur J Pharmacol 2000;406:53-8.","DOI":"10.1016\/S0014-2999(00)00649-X"},{"key":"ref-22","doi-asserted-by":"crossref","unstructured":"Barbanti P, Fabbrini G. Migraine and the extrapyramidal system. Cephalalgia 2002;22:2-11.","DOI":"10.1046\/j.1468-2982.2002.00313.x"},{"key":"ref-23","doi-asserted-by":"crossref","unstructured":"Charbit AR, Akerman S, Goadsby PJ. Comparison of the effects of central and peripheral dopamine receptor activation on evoked firing in the trigeminocervical complex. J Pharmacol Exp Ther 2009;331:752-63.","DOI":"10.1124\/jpet.109.151951"},{"key":"ref-24","doi-asserted-by":"crossref","unstructured":"Barbanti P, Fofi L, Aurilia C, Egeo G. Dopaminergic symptoms in migraine. Neurol Sci 2013;34 Suppl 1:S67-70.","DOI":"10.1007\/s10072-013-1415-8"},{"key":"ref-25","doi-asserted-by":"crossref","unstructured":"Mease PJ, Arnold LM, Crofford LJ, Williams DA, Russell IJ, Humphrey L, et al. Identifying the clinical domains of fibromyalgia: Contributions from clinician and patient Delphi exercises. Arthritis Rheum 2008;59:952-60.","DOI":"10.1002\/art.23826"},{"key":"ref-26","doi-asserted-by":"crossref","unstructured":"Albrecht DS, MacKie PJ, Kareken DA, Hutchins GD, Chumin EJ, Christian BT, et al. Differential dopamine function in fibromyalgia. Brain Imaging Behav 2016;10:829-39.","DOI":"10.1007\/s11682-015-9459-4"},{"key":"ref-27","doi-asserted-by":"crossref","unstructured":"Millan MJ. Descending control of pain. Prog Neurobiol 2002;66:355-474.","DOI":"10.1016\/S0301-0082(02)00009-6"},{"key":"ref-28","doi-asserted-by":"crossref","unstructured":"Joustra ML, Minovic I, Janssens KAM, Bakker SJL, Rosmalen JGM. Vitamin and mineral status in chronic fatigue syndrome and fibromyalgia syndrome: A systematic review and meta-analysis. PLoS One 2017;12:e0176631.","DOI":"10.1371\/journal.pone.0176631"},{"key":"ref-29","doi-asserted-by":"crossref","unstructured":"Riva R, Mork PJ, Westgaard RH, Okkenhaug Johansen T, Lundberg U. Catecholamines and heart rate in female fibromyalgia patients. J Psychosom Res 2012;72:51-7.","DOI":"10.1016\/j.jpsychores.2011.09.010"},{"key":"ref-30","doi-asserted-by":"crossref","unstructured":"Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 2005;52:2495-505.","DOI":"10.1002\/art.21191"},{"key":"ref-31","doi-asserted-by":"crossref","unstructured":"Emamzadeh FN, Surguchov A. Parkinson\u2019s disease: Biomarkers, treatment, and risk factors. Front Neurosci 2018;12:612.","DOI":"10.3389\/fnins.2018.00612"},{"key":"ref-32","doi-asserted-by":"crossref","unstructured":"Yoshimura M, Komori T, Nishimura M, Habuchi Y, Fujita N, Nakanishi T, et al. Diagnostic significance of dopamine estimation using plasma and urine in patients with adrenal and renal insufficiency, renal transplantation and hypertension. Hypertens Res 1995;18 Suppl 1:S87-92.","DOI":"10.1291\/hypres.18.SupplementI_S87"}],"container-title":["Turkish Journal of Physical Medicine and Rehabilitation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ftrdergisi.com\/uploads\/pdf\/pdf_4311.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ftrdergisi.com\/uploads\/pdf\/pdf_4311.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T08:07:59Z","timestamp":1783066079000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ftrdergisi.com\/uploads\/pdf\/pdf_4311.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,3,1]]}},"URL":"https:\/\/doi.org\/10.5606\/tftrd.2022.8529","relation":{},"ISSN":["2587-1250"],"issn-type":[{"value":"2587-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,1]]}}}